HUTCHMED (China) (HCM) EBT (2015 - 2021)

HUTCHMED (China) (HCM) posted quarterly EBT of -$252.5 million for Q4 2021, down 301.31% quarter-over-quarter from -$62.9 million in Q1 2021.

HUTCHMED (China) (HCM) EBT (2015 - 2021) Analysis & Trends

HUTCHMED (China) (HCM) has reported EBT for 6 consecutive years, with -$252.5 million the latest figure, recorded in Q4 2021.

In Q4 2021, EBT changed N/A year-over-year to -$252.5 million; the TTM figure through Dec 2021 stood at -$391.9 million (changed N/A YoY), while the FY2025 annual figure was $64.1 million, up 45294.97% from the prior year.
EBT retreated to -$252.5 million in Q4 2021 per HCM's latest filing, from -$62.9 million in the prior quarter.
Across five years, EBT topped out at $74.4 million in Q2 2018 and bottomed at -$252.5 million in Q4 2021.
Historically, EBT has averaged -$37.2 million across 4 years, with a median of -$32.8 million in 2019.
On a YoY basis, EBT climbed as much as 246.24% in 2019 and fell as far as 362.17% in 2019.
HUTCHMED (China)'s EBT stood at $23.1 million in 2018, then slumped by 266.79% to -$38.5 million in 2019, then declined by 17.67% to -$45.3 million in 2020, then plunged by 457.79% to -$252.5 million in 2021.
Business Quant data shows HCM's EBT at -$252.5 million in Q4 2021, -$62.9 million in Q1 2021, and -$45.3 million in Q2 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBT (Qtr)
1	Haleon	44.07 Bn	43.10 Bn	-	-
2	Teva Pharmaceutical Industries	43.42 Bn	39.76 Bn	2.15 Bn	-455.00 Mn
3	Zoetis	31.86 Bn	30.18 Bn	1.05 Bn	866.00 Mn
4	Takeda Pharmaceutical	28.77 Bn	22.98 Bn	5.10 Bn	1.02 Bn
5	United Therapeutics	22.29 Bn	19.63 Bn	683.80 Mn	372.70 Mn
6	Viatris	18.78 Bn	17.89 Bn	1.46 Bn	-64.00 Mn
7	Neurocrine Biosciences	15.66 Bn	15.27 Bn	935.80 Mn	162.20 Mn
8	Elanco Animal Health	11.91 Bn	11.38 Bn	798.00 Mn	56.00 Mn
9	Dr Reddys Laboratories	10.16 Bn	10.00 Bn	-	-
10	HUTCHMED (China)	2.17 Bn	2.17 Bn	-	-

Download Data